Baptist Memorial Hospital - Tipton
United States
Baptist Memorial Health Care/Mid South NCORP Consortium
The Baptist Memorial Health Care/Mid-South Community NCORP is part of Baptist Memorial Healthcare Corporation (BMHCC), a non-profit faith-based healthcare system with 24 hospitals, 21 outpatient oncology clinics, 8 radiation facilities, and 19 outpatient infusion centers, providing care for approximately 8000 new cancer patients each year. Recent mergers with healthcare systems in rural North, Central and Eastern Mississippi, West Tennessee and Eastern Arkansas have expanded BMHCC’s service area population, to over 125 counties, 4.8 million people across AR, MS, TN, Southwestern Kentucky, Southeastern MO (the bootheel) and Northwestern AL. This rapidly expanding service area covers more than 40% of the 252 counties and parishes in the Delta Regional Authority, which is congressionally acknowledged as the most socio-economically challenged population in the US. BMHCC provides about 30% of cancer care in this demographically, socioeconomically and geographically heterogeneous region, which is also at the heart of the ‘cancer mortality belt of America, with the highest per-capita cancer incidence and mortality rates. Additionally, the region also has fragile public health infrastructure. Before our NCORP, residents of these counties had no reliable access to clinical trials. Since our NCORP began in August 2014, we have rapidly expanded access to clinical trials for our service area population, enrolling more than 150 patients per year, even though the COVID-19 pandemic. Approximately 40% of our enrolled patients are underrepresented groups, 17% reside in rural areas, 13% are uninsured, 21% have Medicaid. Our team members have served in multiple roles to support NCI, NCORP and the various NCORP Research Bases, including service on the NCI Board of Scientific Advisors, CTAC, NCORP taskforces and NCI Steering Committees, such as chairing the Cancer Prevention Steering Committee. We have established Multidisciplinary Care Delivery programs in Breast, Thoracic, Gastrointestinal and Hematologic Oncology to develop Disease-Specific Research Groups that link our clinical trials activities closely to our clinical oncology care programs. This strategy has accelerated our progress. Our system-wide implementation of the Electronic Health Record system, EPIC, has enhanced our research ability, especially in Cancer Care Delivery Research. For the second NCORP funding cycle, we successfully expanded our NCORP research infrastructure across the full extent of BMHCC, with special emphasis on increasing patient recruitment across the state of Mississippi. By leveraging Population Science, Implementation Science and Team Science, we have built a rigorously data-driven clinical trials infrastructure. Our overarching goal remains to improve the quality and outcomes of cancer care delivery to our high-risk population by increasing participation in clinical trials, a goal we have expanded in sequential fashion every year. We support multiple NCORP Research Bases including Alliance, ECOG, SWOG and Wake Forest. Our accrual performance exceeds the requirements for participation as a main member institution of each base. We subscribe to the belief that ‘the best treatment is a clinical trial’.
Publications
- Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, Sharer CW, Burton GV, Kuzma CS, Moseley A, Lew DL, Fisch MJ, Moinpour CM, Hershman DL, Wade JL 3rd. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Feb 1;36(4):326-332. Epub 2017 Nov 14. PMID: 29136387
- Patel JD, Lee JW, Carbone DP, Wagner H, Shanker A, de Aquino MTP, Horn L, Johnson ML, Gerber DE, Liu JJ, Das MS, Al-Nsour MA, Dakhil CSR, Ramalingam S, Schiller JH. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). Clinical lung cancer. 2020 Nov;21(6):520-526. Epub 2020 Jun 12. PMID: 32807654
- Persky DO, Li H, Rimsza LM, Barr PM, Popplewell LL, Bane CL, Von Gehr A, LeBlanc M, Fisher RI, Smith SM, Friedberg JW. A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. American journal of hematology. 2018 Aug;93(4):486-493. Epub 2018 Jan 25. PMID: 29266344
- Goldberg SB, Redman MW, Lilenbaum R, Politi K, Stinchcombe TE, Horn L, Chen EH, Mashru SH, Gettinger SN, Melnick MA, Herbst RS, Baumgart MA, Miao J, Moon J, Kelly K, Gandara DR. Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Dec 1;38(34):4076-4085. Epub 2020 Oct 6. PMID: 33021871
- Ahmad SA, Duong M, Sohal DPS, Gandhi NS, Beg MS, Wang-Gillam A, Wade JL 3rd, Chiorean EG, Guthrie KA, Lowy AM, Philip PA, Hochster HS. Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma. Annals of surgery. 2020 Sep 1;272(3):481-486. PMID: 32740235
- Borghaei H, Redman MW, Kelly K, Waqar SN, Robert F, Kiefer GJ, Stella PJ, Minichiello K, Gandara DR, Herbst RS, Papadimitrakopoulou VA. SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). Clinical lung cancer. 2021 May;22(3):178-186. Epub 2020 Nov 10. PMID: 33358401
- Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Feb 1;39(4):285-294. Epub 2020 Dec 23. PMID: 33356422
- Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Oct;14(10):1853-1859. Epub 2019 Jul 11. PMID: 31302234
- Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 May 15;26(10):2290-2296. Epub 2020 Jan 22. PMID: 31969335
- Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA. A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clinical lung cancer. 2021 May;22(3):170-177. Epub 2020 Oct 14. PMID: 33221175